Key Specifications Table
|Species Reactivity||Key Applications||Host||Format||Antibody Type|
|M, H||WB, IHC||Rb||Serum||Polyclonal Antibody|
|Presentation||Rabbit polyclonal serum with 0.05% sodium azide.|
|Safety Information according to GHS|
|Material Size||100 µL|
Anti-PKM1 Antibody SDS
|Anti-PKM1 - Q2428568||Q2428568|
|Anti-PKM1 - 3422826||3422826|
|Reference overview||Pub Med ID|
|The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth.|
Christofk, Heather R, et al.
Nature, 452: 230-3 (2008) 2008
Many tumour cells have elevated rates of glucose uptake but reduced rates of oxidative phosphorylation. This persistence of high lactate production by tumours in the presence of oxygen, known as aerobic glycolysis, was first noted by Otto Warburg more than 75 yr ago. How tumour cells establish this altered metabolic phenotype and whether it is essential for tumorigenesis is as yet unknown. Here we show that a single switch in a splice isoform of the glycolytic enzyme pyruvate kinase is necessary for the shift in cellular metabolism to aerobic glycolysis and that this promotes tumorigenesis. Tumour cells have been shown to express exclusively the embryonic M2 isoform of pyruvate kinase. Here we use short hairpin RNA to knockdown pyruvate kinase M2 expression in human cancer cell lines and replace it with pyruvate kinase M1. Switching pyruvate kinase expression to the M1 (adult) isoform leads to reversal of the Warburg effect, as judged by reduced lactate production and increased oxygen consumption, and this correlates with a reduced ability to form tumours in nude mouse xenografts. These results demonstrate that M2 expression is necessary for aerobic glycolysis and that this metabolic phenotype provides a selective growth advantage for tumour cells in vivo.